查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840754

甲狀腺癌診斷市場按技術、樣本類型、生物標記類型、應用和最終用戶分類－2025-2032年全球預測

Thyroid Cancer Diagnostics Market by Technology, Sample Type, Biomarker Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，甲狀腺癌診斷市場規模將成長 4.0784 億美元，複合年成長率為 5.91%。

關鍵市場統計數據
基準年 2024 2.5758億美元
預計年份：2025年 2.7314億美元
預測年份 2032 4.0784億美元
複合年成長率 (%) 5.91%

透過將臨床需求、分子創新和診療路徑中的實際操作相結合，建立甲狀腺癌診斷需求框架

甲狀腺癌診斷正處於曲折點，其驅動力源於臨床需求、不斷發展的分子科學以及整個醫療服務體系運作壓力的交匯融合。本執行摘要的引言部分重點闡述了及時、準確且可操作的診斷資訊對於改善患者預後和製定標靶治療策略至關重要的原因。隨著臨床醫生和實驗室負責人尋求減少診斷歧義並實現個體化治療方案，診斷方式的評估不僅著眼於分析性能，還日益關注其與工作流程的兼容性、報銷機制的契合度以及對後續臨床的影響。

因此，支付方和醫療服務提供者越來越重視診斷結果的臨床效用與獲取結果所需資源之間的權衡，檢體可及性、週轉時間和與電子健康記錄的整合等因素也日益受到關注。分子譜分析和輔助檢測技術的進步正在拓展診斷範圍，而不斷更新的臨床指引建議也在重塑檢測流程。因此，相關人員必須權衡高解析度診斷數據的優勢與病理學和實驗室操作的實際限制，以確保創新能夠轉化為患者預後和系統效率的可衡量改善。

識別正在重塑甲狀腺癌診斷方法開發、檢驗和部署方式的變革性技術、臨床和報銷促進因素。

甲狀腺癌的診斷模式正經歷多重變革，這些變革正在改變患者的識別、分層和監測方式。首先，檢測方法正從單一分析物檢測轉向整合遺傳、表觀遺傳和蛋白質訊號的分子譜分析，實現更精細的風險分層。同時，診斷流程也變得更加貼近臨床實際，微創採樣技術和精簡的實驗室流程降低了重複檢測和長期監測的門檻。

其次，科技的快速發展正在改變競爭動態。廣泛應用的定序和數位PCR平台正日趨成熟，預計將實現大規模臨床部署；而先進的免疫組織化學和靈敏的蛋白質檢測技術則正在提升形態學和功能相關性。第三，監管機構和支付方日益嚴格的審查促使診斷技術開發人員更加重視臨床驗證和真實世界證據的產生。最後，數據互通性和分析軟體正成為差異化優勢，幫助臨床醫生將複雜的分子結果轉化為可操作的治療方案。綜上所述，這些轉變表明，成功的診斷策略需要將紮實的科學基礎與切實可行的實證實施路徑結合。

評估2025年關稅如何改變了診斷製造商和實驗室網路的採購、供應鏈彈性和定價。

2025年實施的定向關稅和貿易措施引入了新的變量，影響診斷開發人員和實驗室網路的採購、供應鏈韌性和資本配置。進口耗材和設備的到岸成本因關稅增加而上升，迫使採購團隊重新評估其供應商組合，盡可能加快本地供應商的資格認證，並重新評估高價值臨床檢測的定價策略。為此，儀器供應商和試劑生產商也重新評估了其銷售模式和貿易條款，以緩解利潤率壓縮並維持市場進入。

在營運方面，採用集中採購模式的實驗室正面臨試劑前置作業時間和價格可預測性的不確定性，因此供應商多元化和庫存最佳化具有重要的策略意義。同時，以創新為導向的機構正在探索本地製造夥伴關係和替代籌資策略，以應對未來貿易政策的波動。從臨床營運角度來看，關稅環境凸顯了在控制成本與維持診斷準確性和周轉時間之間取得平衡的必要性，促使各機構加強對特定流程簡化和工作流程效率提升的投資。因此，相關人員應透過加強採購管治、檢驗二級供應商以及記錄維持診斷品質的替代策略，為應對持續的貿易政策不確定性做好準備。

將技術、檢體模式、生物標記類別、臨床應用和最終用戶與可操作的採納路徑和價值促進因素聯繫起來的多維度細分洞察

對診斷方式、檢體類型、生物標記、應用和最終用戶進行嚴格的細分，揭示了甲狀腺癌診斷過程中不同領域的應用動態和臨床價值提案。在技​​術方面，免疫檢測仍然是蛋白質檢測的主流方法，其中化學發光免疫分析和化學冷光免疫檢測試驗（ELISA）在不同形式中探索了不同的靈敏度-通量權衡；次世代定序應用於靶向測序、全外EXOME和全基因組測序，其覆蓋範圍和解讀複雜度各不相同；即時PCR技術包括數字PCR和q22，可實現高靶向度和高峰值測量。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 高解析度超音波彈性成像技術在甲狀腺結節表徵方面的應用日益廣泛
  • 將人工智慧演算法整合到超音波影像中，以提高甲狀腺癌診斷的準確性
  • 分子基因表現分類器在不確定性甲狀腺結節的準確風險分層中應用日益廣泛
  • 對用於識別晚期甲狀腺癌中可標靶突變的次世代定序的需求日益成長
  • 微創消融技術作為低風險乳突甲狀腺腫瘤的治療方法替代方案

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按技術分類的甲狀腺癌診斷市場

  • 免疫檢測
    • 化學冷光免疫檢測
    • ELISA
  • 免疫組織化學
  • 次世代定序
    • 標靶定序
    • 全EXOME定序
    • 全基因組序列分析
  • 即時PCR
    • 數位PCR
    • 定量PCR

9. 甲狀腺癌診斷市場（依樣本類型分類）

  • 血液樣本
  • 細針穿刺法
  • 組織切片檢查

第10章 依生物標記類型分類的甲狀腺癌診斷市場

  • 表觀遺傳標記
    • DNA甲基化
    • miRNA
  • 遺傳標記
    • BRAF
    • RAS
    • TERT
  • 蛋白質標記物
    • 抑鈣素
    • 甲狀腺球蛋白

第11章 依應用分類的甲狀腺癌診斷市場

  • 診斷
  • 預後
  • 復發監測
  • 治療監測

第12章 甲狀腺癌診斷市場（依最終用戶分類）

  • 學術研究機構
    • 癌症研究中心
    • 大學研究實驗室
  • 門診治療中心
    • 影像中心
    • 專科診所
  • 診斷實驗室
    • 連鎖研究所
    • 獨立研究機構
  • 醫院
    • 私立醫院
    • 公立醫院

第13章 各地區甲狀腺癌診斷市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 甲狀腺癌診斷市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國甲狀腺癌診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche AG
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • QIAGEN NV
    • Siemens Healthineers AG
    • Illumina Inc.
    • Hologic, Inc.
    • Danaher Corporation
    • Sysmex Corporation
    • bioMerieux SA
Product Code: MRR-A339DAEFAACE

The Thyroid Cancer Diagnostics Market is projected to grow by USD 407.84 million at a CAGR of 5.91% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 257.58 million
Estimated Year [2025] USD 273.14 million
Forecast Year [2032] USD 407.84 million
CAGR (%) 5.91%

Framing contemporary diagnostic imperatives in thyroid cancer by linking clinical needs with molecular innovation and operational realities across care pathways

Thyroid cancer diagnostics stand at an inflection point driven by a convergence of clinical needs, evolving molecular science, and operational pressures across healthcare delivery systems. The introductory context for this executive summary emphasizes why timely, accurate, and actionable diagnostic information is now central to improving patient trajectories and enabling targeted therapeutic decisions. As clinicians and laboratory leaders seek to reduce diagnostic ambiguity and to personalize care pathways, diagnostic modalities are being evaluated not only for analytical performance but also for workflow compatibility, reimbursement alignment, and downstream clinical impact.

Consequently, payers and providers increasingly weigh the clinical utility of a diagnostic result against the resources required to produce it, which elevates considerations such as sample accessibility, turnaround time, and integration with electronic health records. Advances in molecular profiling and ancillary assays have broadened the diagnostic window, while evolving clinical guideline recommendations are reshaping testing algorithms. Therefore, stakeholders must reconcile the promise of high-resolution diagnostic data with pragmatic constraints within pathology and laboratory operations, to ensure that innovations translate into measurable improvements in patient outcomes and system efficiencies.

Identifying the transformative technological, clinical, and reimbursement-driven shifts that are reshaping how thyroid cancer diagnostics are developed, validated, and deployed

The landscape of thyroid cancer diagnostics is being transformed by several concurrent shifts that are altering how patients are identified, stratified, and monitored. First, there is a palpable shift from single-analyte assays toward integrated molecular profiles that combine genetic, epigenetic, and protein signals, enabling more nuanced risk stratification. At the same time, diagnostic workflows are moving closer to real-world clinical use: less invasive sampling techniques and streamlined laboratory processes are lowering barriers to repeat testing and longitudinal monitoring.

Second, technological diffusion is changing competitive dynamics. Widely adopted platforms for sequencing and digital PCR have reached a level of operational maturity that allows for scaled clinical deployment, while refined immunohistochemistry and high-sensitivity protein assays are improving morphological and functional correlation. Third, regulatory and payer scrutiny is increasing, prompting diagnostics developers to place greater emphasis on clinical validation and real-world evidence generation. Finally, data interoperability and analytic software are emerging as differentiating capabilities, because they enable clinicians to transform complex molecular outputs into actionable treatment pathways. Together, these shifts indicate that successful diagnostics strategies will be those that combine robust science with practical, evidence-based implementation pathways.

Assessing how 2025 tariff measures have reshaped procurement, supply chain resilience, and pricing considerations across diagnostic manufacturers and laboratory networks

The introduction of targeted tariffs and trade measures in 2025 has introduced new variables that influence sourcing, supply chain resilience, and capital allocation across diagnostic developers and laboratory networks. Tariff-related increases in the landed cost of imported consumables and instrumentation have prompted procurement teams to reassess supplier portfolios, accelerate qualification of local vendors where possible, and re-evaluate pricing strategies for high-value clinical tests. In response, instrument vendors and reagent manufacturers have revisited distribution models and commercial terms to mitigate margin compression and to preserve market access.

Operationally, laboratories with centralized procurement have experienced variability in reagent lead times and pricing predictability, which has elevated the strategic importance of supplier diversification and inventory optimization. Meanwhile, innovation-oriented organizations are exploring local manufacturing partnerships and alternative sourcing strategies to buffer against future trade policy volatility. From a clinical operations perspective, the tariff environment has underscored the need to balance cost containment with maintaining diagnostic fidelity and turnaround time, driving selective protocol rationalization and greater investment in workflow efficiencies. As a result, stakeholders should plan for ongoing trade policy uncertainty by strengthening procurement governance, validating secondary suppliers, and documenting substitution strategies that preserve diagnostic quality.

A multidimensional segmentation insight that links technologies, specimen modalities, biomarker classes, clinical applications, and end users to practical adoption pathways and value drivers

A rigorous segmentation-based view of diagnostic modalities, sample types, biomarkers, applications, and end users reveals differentiated adoption dynamics and clinical value propositions across the thyroid cancer diagnostic continuum. Based on Technology, immunoassay remains a mainstay for protein detection and is examined through its chemiluminescence immunoassay and ELISA formats, which offer differing trade-offs in sensitivity and throughput; immunohistochemistry provides pathologic context at the tissue level; next generation sequencing is implemented across targeted sequencing, whole exome sequencing, and whole genome sequencing approaches that vary in breadth and interpretive complexity; and real time PCR technologies include both digital PCR and qPCR platforms that enable sensitive quantitation and targeted mutation detection.

Based on Sample Type, diagnostic pathways rely on blood sample testing for minimally invasive biomarker capture, fine needle aspiration for cytologic evaluation in ambulatory settings, and tissue biopsy for comprehensive histopathologic and molecular assessment. Based on Biomarker Type, the portfolio spans epigenetic markers such as DNA methylation and microRNA signatures, genetic markers including BRAF, RAS, and TERT alterations, and protein markers exemplified by calcitonin and thyroglobulin measurements, each contributing unique diagnostic or prognostic information. Based on Application, testing is organized around diagnosis, prognosis, recurrence monitoring, and therapy monitoring, reflecting the longitudinal needs of clinicians managing thyroid neoplasia. Finally, based on End User, the ecosystem ranges from academic research institutes-encompassing cancer research centers and university laboratories-to ambulatory care centers that include imaging centers and specialized clinics, diagnostic laboratories comprised of chain and independent operators, and hospitals differentiated between private and public facilities, each with distinct procurement, operational, and clinical integration requirements. Taken together, this segmentation highlights how technology choice, specimen accessibility, biomarker selection, clinical purpose, and institutional context collectively determine the design and adoption pathway for diagnostic solutions.

Regional diagnostic ecosystems and adoption dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific that determine access, validation, and clinical integration

Regional dynamics exert a pronounced influence on diagnostic access, regulatory interpretation, and adoption pathways, and insights differ meaningfully across the principal geographies of interest. In the Americas, there is a high level of clinical integration between molecular testing and therapeutic decision-making, supported by advanced laboratory infrastructure and established reimbursement frameworks that favor tests with demonstrated clinical utility. This environment fosters rapid uptake of next generation sequencing panels and highly sensitive protein assays, while also encouraging partnerships between diagnostic developers and large laboratory networks to scale deployment.

In Europe, Middle East & Africa, heterogeneity in regulatory regimes and health system financing yields a more fragmented adoption picture. Certain countries emphasize centralized reference laboratory models and prioritize cost-effectiveness assessments, while others are more permissive toward decentralized testing in ambulatory settings. Across this region, efforts to harmonize nomenclature, reporting standards, and cross-border data sharing are progressing, enabling broader collaborative studies and validation initiatives. In the Asia-Pacific region, investment in diagnostic infrastructure and domestic manufacturing capacity has accelerated, supporting both the local development of assays and rapid clinical uptake in tertiary centers. The region also exhibits a strong appetite for point-of-care solutions and streamlined workflows that address high patient volumes. Across all geographies, regulatory alignment, reimbursement clarity, and supply chain robustness remain decisive factors that shape how diagnostic innovations move from pilot programs to standard clinical practice.

Competitive and collaborative forces among assay developers, platform providers, laboratories, and data vendors that define strategic differentiation and partnership opportunities

Competitive dynamics among diagnostic companies, laboratory networks, and technology providers are increasingly characterized by strategic specialization, platform consolidation, and partnerships that bridge clinical and data capabilities. Leading product strategies emphasize robust clinical validation packages, workflow-friendly instruments, and integrated bioinformatics that translate complex outputs into clinician-ready reports. Companies pursuing differentiation are investing in assay standardization, external quality programs, and physician engagement to demonstrate reproducible clinical utility across diverse patient cohorts.

At the same time, partnership models are expanding: collaborations between assay developers and academic centers facilitate clinical validation and guideline adoption, while alliances with laboratory networks enable scale and geographic reach. Instrument vendors that offer holistic solutions-including sample-to-answer systems, reagent continuity programs, and analytics-are gaining traction with high-volume end users. Emerging players focused on point-of-care devices, AI-driven interpretation, and biomarker discovery are attracting attention, but they must navigate regulatory pathways and demonstrate clinical impact. For stakeholders evaluating potential partners or competitors, the ability to integrate into existing laboratory information systems, to provide clear value propositions for clinicians, and to sustain supply chain reliability will determine success in this evolving landscape.

Actionable strategic recommendations for diagnostics leaders to align clinical validation, supply resilience, payer engagement, and cross-functional commercial execution

Industry leaders should pursue a coordinated set of actions that align technological innovation with clinical validation and operational scalability, thereby accelerating the translation of diagnostic advances into routine care. First, prioritize the generation of robust clinical evidence that links diagnostic outputs to actionable treatment decisions and patient outcomes, and ensure that study designs reflect real-world sample types and workflow constraints. Second, design products and services with interoperable reporting and clinician-friendly interpretive guidance to reduce cognitive load during decision-making and to facilitate adoption across diverse care settings.

Third, strengthen supply chain resilience through multi-source procurement, local manufacturing partnerships where feasible, and contractual commitments for reagent continuity to mitigate the impact of trade volatility. Fourth, engage early with payers and health technology assessment bodies to clarify evidence requirements and establish pathways for reimbursement or value-based contracting. Fifth, invest in partnerships with academic centers and reference laboratories to accelerate validation, develop training programs for pathologists and clinicians, and to create credible clinical champions. Finally, build flexible commercial models that accommodate variable purchasing preferences across academic research institutes, ambulatory care centers, diagnostic laboratories, and hospitals, ensuring alignment with each end user's operational and financial constraints. Executing these priorities will require cross-functional coordination across R&D, regulatory, clinical affairs, supply chain, and commercial teams.

A transparent and evidence-focused research methodology combining literature review, expert interviews, and analytical triangulation to validate clinical and operational diagnostic insights

The research methodology underpinning this executive summary combines structured literature synthesis, targeted expert engagement, and pragmatic synthesis of operational insights to produce actionable conclusions. Primary inputs include peer-reviewed scientific literature on thyroid oncology diagnostics, clinical guideline statements, regulatory documents, and white papers that elucidate analytical and clinical performance characteristics. These sources are complemented by semi-structured interviews with clinicians, laboratory directors, and senior diagnostic executives to surface real-world operational constraints and adoption rationales.

Analytical triangulation was applied to reconcile divergent perspectives, emphasizing cross-validation between clinical utility narratives and laboratory workflow realities. Where possible, technical performance claims for assay platforms were evaluated against published validation studies and proficiency testing outcomes. Key limitations of the methodology include variability in reporting standards across studies and differential availability of real-world evidence for newer technologies. To mitigate these limitations, the approach prioritized high-quality evidence, transparent documentation of assumptions, and iterative validation with subject-matter experts to ensure that conclusions are both relevant and implementable for stakeholders across clinical, laboratory, and commercial functions.

Synthesis and closing insights that emphasize the need for utility-driven innovation, workflow integration, and supply chain resilience to realize diagnostic value in clinical practice

In conclusion, thyroid cancer diagnostics are evolving from discrete assays toward an integrated ecosystem in which molecular profiles, histopathology, and advanced protein testing jointly inform patient management. Progress in sequencing, digital PCR, immunoassays, and interpretive analytics is expanding clinical options, while operational realities such as sample type, laboratory capacity, and procurement constraints influence which innovations are adoptable at scale. Trade policy shifts and regional heterogeneity further underscore the need for adaptable commercialization and supply strategies.

Ultimately, success in this space will be determined by the degree to which diagnostic developers and laboratory operators can demonstrate clinical utility, ensure seamless workflow integration, and maintain supply chain reliability. By aligning product design with clinician needs, regulatory expectations, and end-user operational realities, stakeholders can accelerate the transition of promising technologies from pilot validation to routine clinical use, thereby improving diagnostic precision and patient care pathways across varied healthcare settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of high-resolution ultrasound elastography for improved thyroid nodule characterization
  • 5.2. Integration of artificial intelligence algorithms in ultrasound imaging to enhance diagnostic accuracy in thyroid cancer
  • 5.3. Growing utilization of molecular gene expression classifiers for precise risk stratification in indeterminate thyroid nodules
  • 5.4. Rising demand for next-generation sequencing panels to identify actionable mutations in advanced thyroid carcinoma
  • 5.5. Emergence of minimally invasive ablation techniques as alternative therapies for low-risk papillary thyroid tumors

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Thyroid Cancer Diagnostics Market, by Technology

  • 8.1. Immunoassay
    • 8.1.1. Chemiluminescence Immunoassay
    • 8.1.2. ELISA
  • 8.2. Immunohistochemistry
  • 8.3. Next Generation Sequencing
    • 8.3.1. Targeted Sequencing
    • 8.3.2. Whole Exome Sequencing
    • 8.3.3. Whole Genome Sequencing
  • 8.4. Real Time PCR
    • 8.4.1. Digital PCR
    • 8.4.2. qPCR

9. Thyroid Cancer Diagnostics Market, by Sample Type

  • 9.1. Blood Sample
  • 9.2. Fine Needle Aspiration
  • 9.3. Tissue Biopsy

10. Thyroid Cancer Diagnostics Market, by Biomarker Type

  • 10.1. Epigenetic Markers
    • 10.1.1. DNA Methylation
    • 10.1.2. miRNA
  • 10.2. Genetic Markers
    • 10.2.1. BRAF
    • 10.2.2. RAS
    • 10.2.3. TERT
  • 10.3. Protein Markers
    • 10.3.1. Calcitonin
    • 10.3.2. Thyroglobulin

11. Thyroid Cancer Diagnostics Market, by Application

  • 11.1. Diagnosis
  • 11.2. Prognosis
  • 11.3. Recurrence Monitoring
  • 11.4. Therapy Monitoring

12. Thyroid Cancer Diagnostics Market, by End User

  • 12.1. Academic Research Institutes
    • 12.1.1. Cancer Research Centers
    • 12.1.2. University Laboratories
  • 12.2. Ambulatory Care Centers
    • 12.2.1. Imaging Centers
    • 12.2.2. Specialized Clinics
  • 12.3. Diagnostic Laboratories
    • 12.3.1. Chain Laboratories
    • 12.3.2. Independent Laboratories
  • 12.4. Hospitals
    • 12.4.1. Private Hospitals
    • 12.4.2. Public Hospitals

13. Thyroid Cancer Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Thyroid Cancer Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Thyroid Cancer Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche AG
    • 16.3.2. Abbott Laboratories
    • 16.3.3. Thermo Fisher Scientific Inc.
    • 16.3.4. QIAGEN N.V.
    • 16.3.5. Siemens Healthineers AG
    • 16.3.6. Illumina Inc.
    • 16.3.7. Hologic, Inc.
    • 16.3.8. Danaher Corporation
    • 16.3.9. Sysmex Corporation
    • 16.3.10. bioMerieux S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. THYROID CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. THYROID CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. THYROID CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY QPCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY QPCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY QPCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY QPCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY QPCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD SAMPLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD SAMPLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD SAMPLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD SAMPLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD SAMPLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD SAMPLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DNA METHYLATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DNA METHYLATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DNA METHYLATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DNA METHYLATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DNA METHYLATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DNA METHYLATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY MIRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY MIRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY MIRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY MIRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY MIRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY MIRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BRAF, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BRAF, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BRAF, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BRAF, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BRAF, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BRAF, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TERT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TERT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TERT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TERT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TERT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TERT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CALCITONIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CALCITONIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CALCITONIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CALCITONIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CALCITONIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY THYROGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY THYROGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY THYROGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY THYROGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY THYROGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY THYROGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RECURRENCE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RECURRENCE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RECURRENCE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RECURRENCE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RECURRENCE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RECURRENCE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY THERAPY MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY THERAPY MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY THERAPY MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY THERAPY MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY THERAPY MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY THERAPY MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY UNIVERSITY LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY UNIVERSITY LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY UNIVERSITY LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY UNIVERSITY LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY UNIVERSITY LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY UNIVERSITY LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CHAIN LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CHAIN LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CHAIN LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CHAIN LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CHAIN LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CHAIN LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARK